These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 20590857)

  • 1. Clinical issues in inhibitors.
    Astermark J; Santagostino E; Keith Hoots W
    Haemophilia; 2010 Jul; 16 Suppl 5():54-60. PubMed ID: 20590857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy.
    Kubisz P; Plamenová I; Hollý P; Stasko J
    Med Sci Monit; 2009 Jun; 15(6):CS105-11. PubMed ID: 19488019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitor economics.
    Teitel J
    Semin Hematol; 2006 Apr; 43(2 Suppl 4):S14-7. PubMed ID: 16690371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitors of factor VIII: detection and treatment.
    Brettler DB
    Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():21-5. PubMed ID: 7886576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current status and future prospects for the prophylactic management of hemophilia patients with inhibitor antibodies.
    Teitel JM; Sholzberg M
    Blood Rev; 2013 Mar; 27(2):103-9. PubMed ID: 23452718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemophilia. Strategies for the treatment of inhibitor patients.
    Ingerslev J
    Haematologica; 2000 Oct; 85(10 Suppl):15-20. PubMed ID: 11187863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The benefits of prophylactic treatment with APCC in patients with haemophilia and high-titre inhibitors: a retrospective case series.
    Valentino LA
    Haemophilia; 2009 May; 15(3):733-42. PubMed ID: 19298380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction.
    Leissinger CA
    Am J Hematol; 2004 Oct; 77(2):187-93. PubMed ID: 15389908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.
    Hay CR; Brown S; Collins PW; Keeling DM; Liesner R
    Br J Haematol; 2006 Jun; 133(6):591-605. PubMed ID: 16704433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Successful induction of immune tolerance and novel hemostatic effects in a hemophilia A with high-responder inhibitor by regular infusions of factor VIII].
    Shima M; Sawamoto Y; Kamisue M; Shibata Y; Tuzi S; Kuwabara M; Tanaka I; Tanizawa T; Tanaka A; Ueda M; Kakishita E; Yoshioka A
    Rinsho Ketsueki; 1996 Nov; 37(11):1303-8. PubMed ID: 8960666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors.
    Valentino LA
    Haemophilia; 2010 Mar; 16(2):263-71. PubMed ID: 20028421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylaxis in haemophilia patients with inhibitors.
    Leissinger CA
    Haemophilia; 2006 Dec; 12 Suppl 6():67-72; discussion 72-3. PubMed ID: 17123397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitors in mild/moderate haemophilia A: an update.
    Franchini M; Salvagno GL; Lippi G
    Thromb Haemost; 2006 Aug; 96(2):113-8. PubMed ID: 16894451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experience with a third generation recombinant factor VIII concentrate (Advate) for immune tolerance induction in patients with haemophilia A.
    Valentino LA; Recht M; Dipaola J; Shapiro AD; Pipe SW; Ewing N; Urgo J; Bullock T; Simmons M; Deguzman C
    Haemophilia; 2009 May; 15(3):718-26. PubMed ID: 19298383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spanish Consensus Guidelines on prophylaxis with bypassing agents in patients with haemophilia and inhibitors.
    López-Fernández MF; Altisent Roca C; Álvarez-Román MT; Canaro Hirnyk MI; Mingot-Castellano ME; Jiménez-Yuste V; Cid Haro AR; Pérez-Garrido R; Sedano Balbas C
    Thromb Haemost; 2016 May; 115(5):872-95. PubMed ID: 26842562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How I treat inhibitors in haemophilia.
    Makris M; Hay CR; Gringeri A; D'Oiron R
    Haemophilia; 2012 Jul; 18 Suppl 4():48-53. PubMed ID: 22726083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitors in haemophilia: clinical aspects.
    Dimichele D; Rivard G; Hay C; Antunes S
    Haemophilia; 2004 Oct; 10 Suppl 4():140-5. PubMed ID: 15479387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful low dose immune tolerance induction in severe haemophilia A with inhibitors below 40 Bethesda Units.
    Ter Avest PC; Fischer K; Gouw SC; Van Dijk K; Mauser-Bunschoten EP
    Haemophilia; 2010 May; 16(102):71-9. PubMed ID: 20536988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune tolerance induction therapy for patients with hemophilia A and FVIII inhibitors particularly using low-dose regimens.
    Lin PC; Liao YM; Tsai SP; Chang TT
    Pediatr Blood Cancer; 2011 Dec; 57(6):1029-33. PubMed ID: 21793191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors.
    Reipert BM; van Helden PM; Schwarz HP; Hausl C
    Br J Haematol; 2007 Jan; 136(1):12-25. PubMed ID: 17222196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.